Generation of an Optimal Antibody-Drug Conjugate for Oncology Therapy: Evolving Guiding Principles
Madan Katragadda,
Senior Principal Scientist,
Pfizer
Antibody-drug
conjugates (ADCs) represent a promising therapeutic modality for the clinical
management of cancer. The optimal activity of ADCs requires engineering and
optimization of tumor targeting antibody vehicle, conjugation strategy, and
chemistry of linker-payload. This presentation will touch on some of the
principles or factors that guide the optimization of antibody vehicle to suit
the linker-payload and conjugation chemistry.
|
|
